Comparing Dynavax Technologies (DVAX) and Obseva (OBSV)

Dynavax Technologies (NASDAQ:DVAX) and Obseva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Dynavax Technologies and Obseva’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dynavax Technologies $330,000.00 2,273.30 -$95.15 million ($1.73) -6.92
Obseva N/A N/A -$66.92 million ($2.25) -6.68

Obseva has lower revenue, but higher earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than Obseva, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Dynavax Technologies has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Obseva has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Insider and Institutional Ownership

82.1% of Dynavax Technologies shares are held by institutional investors. Comparatively, 68.3% of Obseva shares are held by institutional investors. 3.5% of Dynavax Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Dynavax Technologies and Obseva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dynavax Technologies -8,570.06% -72.31% -50.92%
Obseva N/A -59.29% -53.39%

Analyst Ratings

This is a breakdown of current ratings and target prices for Dynavax Technologies and Obseva, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dynavax Technologies 0 0 4 0 3.00
Obseva 0 0 7 0 3.00

Dynavax Technologies currently has a consensus price target of $28.25, suggesting a potential upside of 135.81%. Obseva has a consensus price target of $29.86, suggesting a potential upside of 98.78%. Given Dynavax Technologies’ higher possible upside, equities analysts plainly believe Dynavax Technologies is more favorable than Obseva.


Dynavax Technologies beats Obseva on 6 of the 11 factors compared between the two stocks.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

About Obseva

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with's FREE daily email newsletter.

Leave a Reply